Key Findings and Conclusions from MARIPOSA-2 Trial

June 6, 2024

By Martin Dietrich, MD, PhD
Ticiana Leal, MD

Opinion

Video

The panelist summarizes the major findings from MARIPOSA-2 and their conclusions about amivantamab regimens improving outcomes in osimertinib-resistant NSCLC.

EP: 1.Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies

EP: 2.MARIPOSA-2 Phase 3 Study Design and Treatment Arms

EP: 3.Patient Demographics and Baseline Disease Characteristics in MARIPOSA-2

EP: 4.Efficacy Outcomes: Progression-Free Survival, Response Rates, and Duration of Response in MARIPOSA-2

EP: 5.Safety Profile: Adverse Events and Treatment Modifications in MARIPOSA-2

EP: 6.Clinical Practice Implications of MARIPOSA-2 Data and Future Directions

Now Viewing

EP: 7.Key Findings and Conclusions from MARIPOSA-2 Trial

EP: 8.Amivantamab/Chemotherapy May Improve Outcomes in Osimertinib- Resistant EGFR-Mutated NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!